Company Profile

ANUH PHARMA LTD.

NSE : NABSE : 506260ISIN CODE : INE489G01022Industry : Pharmaceuticals & DrugsHouse : Private
BSE115.407.05 (+6.51 % )
PREV CLOSE (Rs.) 108.35
OPEN PRICE (Rs.) 109.05
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 44857
TODAY'S LOW / HIGH (Rs.)109.05 117.00
52 WK LOW / HIGH (Rs.) 66.55 218.7
NSE
This Company is not listed in NSE

Company News

Date Heading Details
29-Jan-2021 Board Meeting Intimation for Intimation Of Board Meeting Dated 9Th February, 2021 & Closure Of Trading Window ANUH PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/02/2021 ,inter alia, to consider and approve Pursuant to the provisions of Regulation 29(1) of the SEBI (LODR) Regulations, 2015, we would like to inform you that the Meeting of the Board of Directors of the Company is scheduled to be held on Tuesday, 9th February, 2021, inter alia: 1) To consider and approve Unaudited Financial Results of the Company for the quarter & nine months ended 31st December, 2020; 2) To consider any other matter with the permission of the Chairman. Further, pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015 and in compliance with the Company's Code of Conduct for prevention of Insider Trading, the Trading window for dealing in the securities of the Company has been closed for the Designated Persons and their immediate relatives, from Thursday, 31st December, 2020 till 48 hours after the declaration of Unaudited Financial Results of the Company for the quarter & nine months ended December 31, 2020 i.e. upto Thursday, 11th February, 2021 (both days inclusive).
08-Jan-2021 Announcement under Regulation 30 (LODR)-Change in Directorate Pursuant to the provisions of Regulation 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that the Board of Directors of the Company (the "Board") at its Meeting held today i.e. Friday, 8th January, 2021, inter-alia considered and approved the following agenda Items: 1.Appointment of Mr. Bipin N. Shah (DIN: 00083244) as a Non-Executive Director and Vice Chairman of the Company with effect from 08th January, 2021, whose period of office shall be liable to retire by rotation; 2.The relinquishment of position of Managing Director by Mr. Bipin N. Shah (DIN: 00083244) for the purpose of Board Restructuring; 3.The appointment and re-designation of Mr. Ritesh B. Shah and Mr. Vivek B. Shah as Joint Managing Directors from the position of Whole Time Directors & Chief Executive Officers for a period of 5 years w.e.f. 8th January, 2021 to 7th January, 2026.
08-Jan-2021 Announcement under Regulation 30 (LODR)-Resignation of Managing Director We wish to inform you that Mr. Bipin N. Shah, Managing Director, relinquished the position of Managing Director of the Company with effect from the closing of business hours of Thursday, 7th January, 2021 for the purpose of Board Restructuring. However, he has been appointed as Non-Executive Director and Vice Chairman of the Company w.e.f. 8th January, 2021.
08-Jan-2021 Outcome Of Board Meeting Held On 08/01/2021 Please note at the Board Meeting held on 08/01/2021, the following items were considered and approved :1)1. Appointment of Mr. Bipin N. Shah as a Non-Executive Director and Vice Chairman of the Company with effect from 08th January, 2021 2) The relinquishment of position of Managing Director by Mr. Bipin N. Shah for the purpose of Board Restructuring 3) The appointment and re-designation of Mr. Ritesh B. Shah and Mr. Vivek B. Shah as Joint Managing Directors from the position of Whole Time Directors & Chief Executive Officers w.e.f. 8th January, 2021 .
08-Jan-2021 Outcome Of Board Meeting Held On 08/01/2021 Please note at the Board Meeting held on 08/01/2021, the following items were considered and approved :1)1. Appointment of Mr. Bipin N. Shah as a Non-Executive Director and Vice Chairman of the Company with effect from 08th January, 2021 2) The relinquishment of position of Managing Director by Mr. Bipin N. Shah for the purpose of Board Restructuring 3) The appointment and re-designation of Mr. Ritesh B. Shah and Mr. Vivek B. Shah as Joint Managing Directors from the position of Whole Time Directors & Chief Executive Officers w.e.f. 8th January, 2021 .
08-Jan-2021 Appointment of Chairman inter alia, approved 1. Appointment of Mr. Bipin N. Shah as a Non-Executive Director and Vice Chairman of the Company with effect from 08th January, 2021 2) The relinquishment of position of Managing Director by Mr. Bipin N. Shah for the purpose of Board Restructuring 3) The appointment and re-designation of Mr. Ritesh B. Shah and Mr. Vivek B. Shah as Joint Managing Directors from the position of Whole Time Directors & Chief Executive Officers w.e.f. 8th January, 2021 .
30-Sep-2020 Anuh Pharma jumps on getting approval for Pyrimcthamine API <P align=justify>Anuh Pharma is currently trading at Rs. 194.50, up by 4.60 points or 2.42% from its previous closing of Rs. 189.90 on the BSE.<BR><P align=justify>The scrip opened at Rs. 194.45 and has touched a high and low of Rs. 195.30 and Rs. 186.00 respectively. So far 22586 shares were traded on the counter.<BR><P align=justify>The BSE group 'X' stock of face value Rs. 5 has touched a 52 week high of Rs. 218.70 on 25-Aug-2020 and a 52 week low of Rs. 48.70 on 24-Mar-2020.<BR><P align=justify>Last one week high and low of the scrip stood at Rs. 207.80 and Rs. 182.00 respectively. The current market cap of the company is Rs. 967.66 crore.<BR><P align=justify>The promoters holding in the company stood at 72.09%, while Non-Institutions held 27.90% stake in the company.<P align=justify>Anuh Pharma has received approval from World Health Organization (WHO) - Geneva Prequalification for Pyrimcthamine API which is used as Anti - Malarial Durgs.<P align=justify>Anuh Pharma is one of the leading manufacturers of Active Pharmaceutical Ingredients (APIs) and a leading importer, exporter, distributor and manufacturer of bulk drugs, chemicals and pharmaceutical formulations.<BR>
29-Sep-2020 Anuh Pharma gets approval for Pyrimcthamine API <p align="justify">Anuh Pharma has received approval from World Health Organization (WHO) - Geneva Prequalification for Pyrimcthamine API which is used as Anti - Malarial Durgs.<br></p><p align="justify">Anuh Pharma is one of the leading manufacturers of Active Pharmaceutical Ingredients (APIs) and a leading importer, exporter, distributor and manufacturer of bulk drugs, chemicals and pharmaceutical formulations.</p>
29-Jul-2020 Anuh Pharma informs about board meeting <P align=justify>Pursuant to the provisions of Regulation 29(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Anuh Pharma has informed that the Meeting of the Board of Directors of the Company is scheduled to be held on Friday, 7th August, 2020, to consider and approve Unaudited Financial Results of the Company for the quarter ended 30th June, 2020, to consider the proposal of Bonus Issue of Equity Shares, to fix the record date and to consider any other matter with the permission of the Chairman. Further, pursuant to the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 and in compliance with the Company's Code of Conduct for prevention of Insider Trading, the Trading window for dealing in the securities of the Company has been closed for the Designated Persons and their immediate relatives, from Wednesday, 1st July, 2020 till 48 hours after the declaration of Unaudited Financial Results of the Company for the quarter ended June 30, 2020 up to Sunday, 9th August, 2020.<P align=justify>The above information is a part of company's filings submitted to BSE.<BR>
04-May-2020 Anuh Pharma informs about compliance certificate <P align=justify>Pursuant to the provisions of Regulation 7(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 [SEBI (LODR), 2015], Anuh Pharma has informed that it has enclosed the Compliance Certificate for the half year ended on March 31, 2020 jointly signed by authorised representative of Bigshare Services, Registrar and Share Transfer Agent of the Company certifying compliance with the requirements of Regulation 7(2) of the SEBI (LODR), 2015.<BR><P align=justify>The above information is a part of company's filings submitted to BSE.